PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, an oral, steroid-sparing immunomodulator for diseases driven by dysregulated inflammation, today announced the presentation of new preclinical data in atopic dermatitis (AD) at the 2026 European…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company at the forefront of immunologic research, today announced the addition of two distinguished scientists to its Scientific Advisory Board (SAB): Dr. Michael Wechsler, and Dr. Johann Gudjonsson. These…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes Wolff, MD, PhD, as Chief Medical Officer (CMO) and Michael D. Howell,…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investigational New Drug (IND) application enabling studies will be presented at…